PrEP Use Rising, But Uptake Lags Among Women, People of Color
By Kim Krisberg, Since its approval over a decade ago, medication that protects people from being infected with HIV has been a driving factor behind the country’s declining HIV numbers. But considerable inequities remain, with those most at risk least likely to be taking HIV prevention drugs. Data released last year by AIDSVu, an HIV mapping initiative at Emory University, found that while pre-exposure prophylaxis medication use has gone up each year since the US Food and Drug Administration approved a daily pill in 2012, Black and Hispanic people, as well as residents living in the South, have disproportionately low